High diagnostic efficacy of 5-aminolevulinic acid-induced fluorescent urine cytology for urothelial carcinoma.


Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 29 11 2018
accepted: 04 04 2019
pubmed: 13 4 2019
medline: 27 11 2019
entrez: 13 4 2019
Statut: ppublish

Résumé

In general, urine cytology is often problematic because of its low sensitivity, especially for low-grade urothelial carcinoma (UC) in clinical practice. To improve the sensitivity, we focused on 5-aminolevulinic acid (5-ALA), because recent studies suggested that 5-ALA-induced urine cytology can be used for photodynamic diagnosis. In this study, we evaluated the diagnostic efficacy of 5-ALA-induced fluorescent urine cytology for UC. We included in this study 318 patients comprising 158 non-cancer patients, 84 bladder tumor patients, and 76 upper urinary tract urothelial carcinoma (UUT-UC) patients treated in our institution from March 2013 to September 2018. Using the same voided urine sample, we compared sensitivity and specificity between conventional urine cytology and 5-ALA-induced fluorescent urine cytology. Overall, the sensitivity of 5-ALA-induced fluorescent urine cytology was significantly higher than that of conventional urine cytology (86.9% vs. 69.4%; p = 0.0002), and the specificity was equivalently high (96.2% vs. 95.6%; p = 1.0). In subgroup analysis, the high sensitivity of 5-ALA-induced fluorescent urine cytology was also detected regardless of age, sex, and tumor type. However, in terms of stage and grade, differences were only detected in patients with less than pTa stage (89.2% vs. 52.1%; p = 0.0001) and low-grade tumor (91.5% vs. 51.1%; p < 0.0001). 5-ALA-induced fluorescent urine cytology was significantly more effective for UC diagnosis when compared with the conventional cytology, especially in patients with low-stage and low-grade tumors. These findings indicate that 5-ALA-induced fluorescent urine cytology may potentially be a very useful tool for clinical use.

Sections du résumé

BACKGROUND BACKGROUND
In general, urine cytology is often problematic because of its low sensitivity, especially for low-grade urothelial carcinoma (UC) in clinical practice. To improve the sensitivity, we focused on 5-aminolevulinic acid (5-ALA), because recent studies suggested that 5-ALA-induced urine cytology can be used for photodynamic diagnosis. In this study, we evaluated the diagnostic efficacy of 5-ALA-induced fluorescent urine cytology for UC.
METHODS METHODS
We included in this study 318 patients comprising 158 non-cancer patients, 84 bladder tumor patients, and 76 upper urinary tract urothelial carcinoma (UUT-UC) patients treated in our institution from March 2013 to September 2018. Using the same voided urine sample, we compared sensitivity and specificity between conventional urine cytology and 5-ALA-induced fluorescent urine cytology.
RESULTS RESULTS
Overall, the sensitivity of 5-ALA-induced fluorescent urine cytology was significantly higher than that of conventional urine cytology (86.9% vs. 69.4%; p = 0.0002), and the specificity was equivalently high (96.2% vs. 95.6%; p = 1.0). In subgroup analysis, the high sensitivity of 5-ALA-induced fluorescent urine cytology was also detected regardless of age, sex, and tumor type. However, in terms of stage and grade, differences were only detected in patients with less than pTa stage (89.2% vs. 52.1%; p = 0.0001) and low-grade tumor (91.5% vs. 51.1%; p < 0.0001).
CONCLUSIONS CONCLUSIONS
5-ALA-induced fluorescent urine cytology was significantly more effective for UC diagnosis when compared with the conventional cytology, especially in patients with low-stage and low-grade tumors. These findings indicate that 5-ALA-induced fluorescent urine cytology may potentially be a very useful tool for clinical use.

Identifiants

pubmed: 30976938
doi: 10.1007/s10147-019-01447-5
pii: 10.1007/s10147-019-01447-5
doi:

Substances chimiques

Aminolevulinic Acid 88755TAZ87

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1080

Références

BJU Int. 2001 Nov;88(7):692-701
pubmed: 11890239
J Urol. 2003 Jun;169(6):1975-82
pubmed: 12771702
JAMA. 2006 Jan 18;295(3):299-305
pubmed: 16418465
Curr Opin Urol. 2006 Sep;16(5):372-6
pubmed: 16905985
World J Urol. 2008 Feb;26(1):51-8
pubmed: 18058108
Eur Urol. 2008 Jun;53(6):1138-48
pubmed: 18096307
Photochem Photobiol Sci. 2008 Mar;7(3):283-9
pubmed: 18389144
Cancer. 2012 Feb 15;118(4):1062-74
pubmed: 21773973
Radiology. 2012 Jul;264(1):110-8
pubmed: 22495683
Photodiagnosis Photodyn Ther. 2013 Sep;10(3):288-95
pubmed: 23993855
Photodiagnosis Photodyn Ther. 2015 Jun;12(2):282-8
pubmed: 25595357
Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200
pubmed: 25843912
Eur Urol. 2015 Nov;68(5):868-79
pubmed: 26188393
Photodiagnosis Photodyn Ther. 2016 Mar;13:225-232
pubmed: 26226642
Urology. 2016 Oct;96:35-43
pubmed: 27151340
J Cancer Res Clin Oncol. 2017 Nov;143(11):2309-2316
pubmed: 28726046
BJU Int. 2018 Feb;121(2):184-193
pubmed: 29032580
Int J Clin Oncol. 2018 Dec;23(6):1140-1147
pubmed: 29971622
Br J Cancer. 1987 Nov;56(5):589-95
pubmed: 3480752
Urology. 1994 Dec;44(6):836-41
pubmed: 7985312
Cancer. 1994 Sep 1;74(5):1621-6
pubmed: 8062194
Photochem Photobiol. 1995 Nov;62(5):887-95
pubmed: 8570728

Auteurs

Gaku Yamamichi (G)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Wataru Nakata (W)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan. nakata_wa@osakah.johas.go.jp.

Masaru Tani (M)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Go Tsujimura (G)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Yuichi Tsujimoto (Y)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Mikio Nin (M)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Akihiro Mimura (A)

Department of Laboratory Medicine, Osaka Rosai Hospital, Osaka, Japan.

Hideaki Miwa (H)

Department of Diagnostic Pathology, Osaka Rosai Hospital, Osaka, Japan.

Masao Tsujihata (M)

Department of Urology, Osaka Rosai Hospital, Nagasone-cho 1179-3, Kitaku, Sakaishi, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH